
Regeneron Pharmaceuticals, Inc.
-0.2 %
-26.51 %
Yet to be announced
Company Overview
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases. The company's product portfolio and pipeline focus on eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases.
The company's key marketed products include EYLEA (aflibercept) for eye diseases, Dupixent (dupilumab) for allergic diseases, Praluent (alirocumab) for cholesterol management, and Libtayo (cemiplimab) for cancer treatment.
Revenue Sources
PassBased on analysis of Regeneron's revenue sources from SEC filings and financial reports, the company's primary revenue streams come from the development and sale of legitimate pharmaceutical products. The company does not derive material revenue from prohibited sources such as alcohol, gambling, or other haram activities.
Reliance on Interest
Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
Dec. 31, 2024 | $3.79b | $2.81b | - | $10.5m | 0.00% | 0.37% |
Sept. 30, 2024 | $3.72b | $2.56b | - | $13.8m | 0.00% | 0.54% |
June 30, 2024 | $3.55b | $2.49b | - | $14.8m | 0.00% | 0.59% |
March 31, 2024 | $3.15b | $2.41b | - | $16.1m | 0.00% | 0.67% |
Examining the last four quarters of financial data, Regeneron's interest expense represents a minimal portion of total expenses. The interest expense ratios for all quarters were well below the 5% threshold. The company maintains a strong operational focus with interest expenses being incidental to its core business operations rather than a material source of income or expense.
Operational Ethics
PassBased on review of company documents, press releases, and public information, there is no evidence of material ongoing collaboration with entities involved in human rights violations. While the company conducts business globally, there are no documented substantial ties to the Chinese Communist Party or the state of Israel that would raise concerns.
Login to join the discussion